Asset Details
Do you wish to reserve the book?
VENOUS THROMBOEMBOLISM: WHAT PHARMACISTS KNOW? WHAT DO THEY NEED?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
VENOUS THROMBOEMBOLISM: WHAT PHARMACISTS KNOW? WHAT DO THEY NEED?
Do you wish to request the book?
VENOUS THROMBOEMBOLISM: WHAT PHARMACISTS KNOW? WHAT DO THEY NEED?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
VENOUS THROMBOEMBOLISM: WHAT PHARMACISTS KNOW? WHAT DO THEY NEED?
2022
Overview
Vnous thromboembolism is frequent in cancer. Low molecular weight heparins (LMWH) are recommended for prevention/treatment of thrombosis in cancer Community pharmacists are very often faced with patients' questions (dosage, tolerance, treatment duration). The aim of this study was to assess the community pharmacists' knowledge regarding 'thrombosis in cancer'. A web-questionnaire (built by a multidisciplinary group) was open between October and November 2013 to community pharmacists in Champgne-Ardenne region. Collected data were 1) pharmacy's general organization for cancer patients' management, 2) management of ambulatory patients with 'thrombosis and cancer ' and 3) pharmacists' knowledge assessment through a simple case report: after an initial 10-days hospital prescription, what should a patient receive as anticoagulant treatment?' One hundred eighty (38 %) community pharmacists answered the questionnaire. Among those, in 65 %, the number of patients with cancer was 6-15/pharmacy In 70 % the number of patients with thrombosis and cancer was 1-10/pharmacy This regional questionnaire will be extended to all French regions. Continuous education sessions are being put in place. Another questionnaire will be launched at the end of 2014 to assess education sessions' efficacy.
Publisher
Springer
Subject
